Actitrexx Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $4.14M

  • Investors
  • 10

Actitrexx General Information

Description

Developer of a cell therapy technology designed for the treatment of patients after a stem cell transplant to prevent rejection reactions. The company's technology focuses on the development of clinical testing of cell therapeutics for the suppression of transplant rejection and autoimmunity, and the portfolio of cell therapy, enabling healthcare professionals to prevent the fatal consequences of rejection, significantly improving their quality of life, and also opening up to many therapy options.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Langenbeckstrasse 1, Building 401
  • C/o University Medical Center Mainz, Johannes Gutenberg-University Mainz
  • 55131 Mainz
  • Germany
+49 06131
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Langenbeckstrasse 1, Building 401
  • C/o University Medical Center Mainz, Johannes Gutenberg-University Mainz
  • 55131 Mainz
  • Germany
+49 06131

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Actitrexx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series A) 30-Nov-2020 $4.14M Completed Clinical Trials - Phase 1
3. Accelerator/Incubator Completed Startup
2. Grant 20-Jul-2018 $2.33K Completed Startup
1. Grant 01-Jan-2016 $4.35M Completed Startup
To view Actitrexx’s complete valuation and funding history, request access »

Actitrexx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a cell therapy technology designed for the treatment of patients after a stem cell transplant to prevent re
Drug Discovery
Mainz, Germany
11 As of 2023

Madison, WI
 

Basel, Switzerland
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Actitrexx Competitors (34)

One of Actitrexx’s 34 competitors is Centrose, a Venture Capital-Backed company based in Madison, WI.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Centrose Venture Capital-Backed Madison, WI
Baliopharm Venture Capital-Backed Basel, Switzerland
Sorrento Therapeutics Formerly VC-backed San Diego, CA
Topas Therapeutics Venture Capital-Backed Hamburg, Germany
Toleranzia Private Equity-Backed Gothenburg, Sweden
You’re viewing 5 of 34 competitors. Get the full list »

Actitrexx Patents

Actitrexx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4806433-A1 Combination of immunomodulatory agent and activated treg for treating autoimmune and autoinflammatory diseases Pending 14-Mar-2025
WO-2026190367-A1 Combination of immunomodulatory agent and activated treg for treating autoimmune diseases Pending 14-Mar-2025
EP-4806432-A1 Combination of immunomodulatory agent and treg activator for the treatment of an autoimmune and autoinflammatory disease Pending 14-Mar-2025
WO-2026190366-A1 Combination of immunomodulatory agent and treg activator for the treatment of an autoimmune and autoinflammatory disease Pending 14-Mar-2025
US-10729742-B2 Screening method for the identification of agents capable of activating cd4+cd25+ regulatory t-cells through interactions with the hiv-1 gp120 binding site on cd4 Active 01-Feb-2007 A61K38/162
To view Actitrexx’s complete patent history, request access »

Actitrexx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Actitrexx Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
High-Tech Gründerfonds Venture Capital Minority
Investitions- und Strukturbank Rheinland-Pfalz Venture Capital Minority
LBBW Venture Capital Corporate Venture Capital Minority
MediVentures Venture Capital Minority
Rheinland-Pfalz Fonds Corporation Minority
You’re viewing 5 of 10 investors. Get the full list »

Actitrexx FAQs

  • When was Actitrexx founded?

    Actitrexx was founded in 2016.

  • Where is Actitrexx headquartered?

    Actitrexx is headquartered in Mainz, Germany.

  • What is the size of Actitrexx?

    Actitrexx has 11 total employees.

  • What industry is Actitrexx in?

    Actitrexx’s primary industry is Drug Discovery.

  • Is Actitrexx a private or public company?

    Actitrexx is a Private company.

  • What is Actitrexx’s current revenue?

    The current revenue for Actitrexx is .

  • How much funding has Actitrexx raised over time?

    Actitrexx has raised $4.14M.

  • Who are Actitrexx’s investors?

    High-Tech Gründerfonds, Investitions- und Strukturbank Rheinland-Pfalz, LBBW Venture Capital, MediVentures, and Rheinland-Pfalz Fonds are 5 of 10 investors who have invested in Actitrexx.

  • Who are Actitrexx’s competitors?

    Centrose, Baliopharm, Sorrento Therapeutics, Topas Therapeutics, and Toleranzia are some of the 34 competitors of Actitrexx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process